

Table 8. Cost-effectiveness results (one-way sensitivity analysis).

	ICUR (€)	ICER (€)
<i>Base-case</i>	19,951	13,123
<i>Discount rate</i> 3.5%* (NICE, [4039])	19,985	13,179
<i>Risk of recurrences (over the 5-year follow-up)</i>		
20%	40,228	26,468
30%	24,474	16,100
40%	16,544	10,881
50%	11,737	7,718
<i>Treatment-related mortality (salvage surgery)</i>		
0% [124]	20,011	13,052
5% [398]	19,931	13,147
<i>Treatment-related mortality (re-irradiation)</i>		
0% [8]	19,971	13,099
11% [8]	19,925	13,154
<i>Salvage surgery (cost, €)</i>		
5,281 (hospitals without emergency department)	19,849	13,056
5,607 (hospital with emergency department)	20,052	13,190
<i>Cost in 'no evidence of disease' state after salvage treatment (arm B)</i>		
91.9 (up to year 3th) and 15.3 (from the 4th year)	22,480	14,787

*corresponding to 0.287% monthly; NICE: National Institute for Clinical Excellence. ICER: incremental cost-effectiveness ratio; ICUR: incremental cost-utility ratio.